Bortezomib’s efficacy for solid tumors is inadequate due to resistance to cell death induction (30); nevertheless, insertion of arginylated calreticulin into the plasma membrane of glioma cells treated with bortezomib can initiate the apoptotic pathway (63). This evidence concerns the gene CALR and central nervous system cancer.